title: Bevacizumab rechallenge after first line maintenance bevacizumab.
authors.forename: Panagiotis A
authors.initials: PA
authors.lastname: Konstantinopoulos
authors.forename: Suzanne T
authors.initials: ST
authors.lastname: Berlin
authors.forename: Susana M
authors.initials: SM
authors.lastname: Campos
authors.forename: Ursula A
authors.initials: UA
authors.lastname: Matulonis
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Cannistra
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D004334:Drug Administration Schedule; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D012008:Recurrence
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab